Landon Capital

Ocugen, Inc. (Nasdaq:OCGN) is a biopharmaceutical company that develops therapies for diseases of the eye. Its lead product candidate is designed to treat patients with a rare genetic disorder that causes blindness, and the company has several other product candidates in its pipeline. Its mission is to develop innovative treatments that improve the lives of patients with vision disorders.

Comps: Nkarta, Inc. (Nasdaq:NKTX), Rallybio Corporation (Nasdaq:RLYB)

While it is important to note that these companies are not currently generating revenue, Ocugen still stands out in a few important metrics. Notably, its earnings per share are more favorable than those of its counterparts. Furthermore, its debt-to-equity ratio and net income are better than Nkarta’s.